Suggested remit: To appraise the clinical and cost effectiveness of ranibizumab port delivery system within its marketing authorisation for treating wet age-related macular degeneration.
- Status:
- Awaiting development
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 3983
Provisional Schedule
- Committee meeting:
- 08 September 2026
- Expected publication:
- 11 November 2026
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email TACommC@nice.org.uk
- External Assessment Group:
- BMJ Technology Assessment Group (BMJ-TAG), BMJ
Stakeholders
- Companies sponsors
- Roche (port delivery platform with ranibizumab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Eyecare Trust
- Fight for Sight
- Macular Society
- National Federation of the Blind of the UK
- Network of Sikh Organisations
- Royal National Institute of Blind People
- SeeAbility
- Sense
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Thomas Pocklington Trust
- Professional groups
- Association of Optometrists
- British and Eire Association of Vitreoretinal Surgeons
- British and Irish Orthoptic Society
- British Geriatrics Society
- British Ophthalmic Anaesthesia Society
- College of Optometrists
- Optical Confederation
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Ophthalmologists
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- UK Clinical Pharmacy Association
- UK Ophthalmic Pharmacy Group
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- ADVANZ Pharma (aflibercept)
- Bayer (aflibercept)
- Celltrion Healthcare (aflibercept)
- Genus Pharmaceuticals (ranibizumab)
- MDBiologics (aflibercept)
- Novartis (brolucizumab, ranibizumab)
- Orion Pharma (ranibizumab)
- Outlook Therapeutics (bevacizumab gamma)
- Roche (faricimab)
- Samsung Bioepis (ranibizumab)
- Sandoz (aflibercept)
- Teva UK (ranibizumab)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Wales Council for the Blind
- Welsh Government
- Relevant research groups
- Cochrane Eyes and Vision Group
- Cochrane UK
- Eye Hope
- Genomics England
- Institute of Ophthalmology, University College London
- MRC Clinical Trials Unit
- National Eye Research Centre Charity
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 06 February 2026 | Invitation to participate |
| 10 December 2025 - 08 January 2026 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 18 June 2025 | Awaiting development. Please note that the timelines for this appraisal are anticipated to begin in early February 2026 with submissions expected in mid-April 2026. |
| 26 December 2022 | As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of the Port Delivery System with ranibizumab for treating wet age-related macular degeneration. Please note that following on from advice received from the company the timelines for this appraisal are to be confirmed. The appraisal will be rescheduled to align with latest regulatory expectations and an update on the revised timelines will be provided when further information is available. |
| 14 September 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 01 July 2022 | As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Ranibizumab port delivery system for treating wet age-related macular degeneration. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early October 2022. These timings are based on a request from the company to reschedule the initial date set by NICE. |
| 31 May 2022 | The topic was discussed at the Topic Selection Oversight Panel (TSOP) in April 2022. The panel concluded that the topic was suitable for a Technology Appraisal. Following conversations with the company, the scheduling of the evaluation is to be confirmed and stakeholders will be updated in due course. |
| 31 May 2022 | Topic selection. The topic was discussed at the Topic Selection Oversight Panel (TSOP) in April 2022. The panel concluded that the topic was suitable for a Technology Appraisal. Following conversations with the company, the scheduling of the evaluation is to be confirmed and stakeholders will be updated in due course. |
| 26 January 2022 - 23 February 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 26 January 2022 | In progress. In progress |
| 26 January 2022 | In progress. . |
For further information on our processes and methods, please see our CHTE processes and methods manual